Wockhardt Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016
January 24, 2017 at 04:32 pm IST
Share
Wockhardt Limited reported unaudited standalone and consolidated earnings results for the third quarter and nine months ended December 31, 2016. For the quarter on standalone basis, the company reported net sales/income from operations of INR 5,453.5 million against INR 6,288.3 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 115.4 million against profit from operations before other income, finance costs and exceptional items of INR 938.1 million a year ago. Loss from ordinary activities before tax was INR 261.6 million against profit from ordinary activities before tax of INR 861.3 million a year ago. Net loss after tax before other comprehensive income was INR 194.6 million against net profit after tax before other comprehensive income of INR 842.4 million a year ago. Diluted loss per share was INR 1.80 per against diluted earnings per share of INR 7.57 per share a year ago.
For the nine months on standalone basis, the company reported net sales/income from operations of INR 17,569.8 million against INR 17,081.9 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 112.0 million against INR 485.6 million a year ago. Loss from ordinary activities before tax was INR 1,171.7 million against INR 149.9 million a year ago. Net profit after tax before other comprehensive income was INR 1,430.3 million against INR 76 million a year ago. Diluted earnings per share was INR 12.84 per against INR 0.68 per share a year ago.
For the quarter on consolidated basis, the company reported net sales/income from operations of INR 9,955.6 million against INR 10,745.1 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 199.9 million against profit from operations before other income, finance costs and exceptional items of INR 380.2 million a year ago. Loss before tax was INR 761.6 million against profit before tax of INR 475.5 million a year ago. Net loss for the period was INR 604.4 million against net profit for the period of INR 691.4 million a year ago. Diluted loss per share was INR 4.88 per against diluted earnings per share of INR 6.47 per share a year ago.
For the nine months on consolidated basis, the company reported net sales/income from operations of INR 31,242.6 million against INR 34,429.7 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 910.2 million against INR 3,326.3 million a year ago. Loss before tax was INR 432.0 million against INR profit before tax of 2,856.7 million a year ago. Net loss for the period was INR 188.2 million against net profit for the period of INR 2,645.5 million a year ago. Diluted loss per share was INR 1.90 per against diluted earnings per share of INR 23.02 per share a year ago.
Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It manufactures a range of dosage forms, including sterile injectables and lyophilized products. The Company offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Companyâs products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. It has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.